Nomenclature	S-Adenosylmethionine decarboxylase	L-Arginine decarboxylase	L-Aromatic amino-acid decarboxylase	Glutamic acid decarboxylase 1	Glutamic acid decarboxylase 2
Common abbreviation	SAMDC	ADC	AADC	GAD1	GAD2
HGNC, UniProt	AMD1, P17707	ADC, Q96A70	DDC, P20711	GAD1, Q99259	GAD2, Q05329
EC number	4.1.1.50	4.1.1.19	4.1.1.28: L-DOPA -> dopamine + CO2	4.1.1.15: L-glutamic acid + H+ -> GABA + CO2	4.1.1.15: L-glutamic acid + H+ -> GABA + CO2
Endogenous substrates	S-adenosyl methionine	L-arginine	L-tryptophan, L-DOPA, 5-hydroxy-L-tryptophan	L-glutamic acid, L-aspartic acid	L-glutamic acid, L-aspartic acid
Products	5′-deoxyadenosyl-(3-aminopropyl) methylsulfonium	agmatine 43	5-HT, dopamine	GABA	GABA
Cofactors	pyruvic acid	pyridoxal phosphate	pyridoxal phosphate	pyridoxal phosphate	pyridoxal phosphate
Selective inhibitors (pIC50)	SAM486A (8.0) 41	–	3-hydroxybenzylhydrazine, benserazide, carbidopa, L-α-methyldopa	s-allylglycine	s-allylglycine
Comment	s-allylglycine is also an inhibitor of SAMDC 39	The presence of a functional ADC activity in human tissues has been questioned 36	AADC is a homodimer. Reaction 1: L-DOPA -> dopamine + CO2, Reaction 2: 5-hydroxy-L-tryptophan -> 5-HT + CO2, Reaction 3: L-tryptophan -> tryptamine + CO2	L-aspartic acid is a less rapidly metabolised substrate of mouse brain glutamic acid decarboxylase generating β-alanine 42. Autoantibodies against GAD1 and GAD2 are elevated in type 1 diabetes mellitus and neurological disorders (see Further reading)